Table 3.

Sensitivity analysis parameter’s ranges and distribution

Variable	Baseline value	Range		Distribution	References
		Minimum	Maximum
Costs per cycle, $ in China
Before disease progression cost per month
Administration	21	17	25	Gamma	19 21
Examination	160	127	191	Gamma	19 21
Outpatient visit	3	3.6	2.4	Gamma	19 21
Cost of endocrine drug treatment
Costs on F&A arm
FUL in first cycle	2753.4	2202.7	3304.08	Gamma	19 21
FUL in subsequent cycles	688.36	550.69	826	Gamma	19 21
ANA cost	139	111	167	Gamma	19 21
Cost on FUL arm
FUL in first cycle	4130.15	3304.12	4956.18	Gamma	19 21
FUL in subsequent cycles	1376.72	1101.38	1652.06	Gamma	19 21
Management of SAEs	362	272	453	Gamma	19 21
After progression cost per month
Subsequent medication therapy	6664.04	5332.23	7996.86	Gamma	19 21
Hospitalisation	127.68	102.14	153.21	Gamma	19 21
Outpatient visit	29.18	23.35	35.02	Gamma	19 21
Laboratory evaluations	189.18	151.34	227.01	Gamma	19 21
Utilities
PFS	0.76	0.61	0.91	Beta	24–27
PD	0.55	0.54	0.56	Beta	24–27
Disutilities
Stomatitis	0.13	0.117	0.143	Beta	24–27
Constipation	0.03	0.02	0.04	Beta	24–27
Cough	0.05	0.045	0.055	Beta	24–27
Insomnia	0.2	0.18	0.22	Beta	24–27
Non-infectious pneumonia	0.05	0.045	0.055	Beta	24–27
Fatigue	0.1	0.09	0.11	Beta	24–27
Hot flashes	0.03	0	0.06	Beta	24–27
Arthralgia	0.18	0.162	0.198	Beta	24–27
Anorexia	0.03	0.02	0.04	Beta	24–27
Diarrhoea	0.09	0.081	0.099	Beta	24–27
Headache	0.12	0.108	0.132	Beta	24–27
Dyspepsia	0.09	0.081	0.099	Beta	24–27
Musculoskeletal pain	0.07	0.05	0.09	Beta	24–27
Nausea/vomiting	0.09	0.081	0.099	Beta	24–27

ANA, anastrozole; ANA, anastrozole; F&A, half-dose fulvestrant plus anastrozole treatment group; F&A, half-dose fulvestrant plus anastrozole treatment group; FUL, fulvestrant;FUL, fulvestrant;PD, progressed disease; PD, progressed disease; PFS, progression free survival; PFS, progression-free survival; SAE, serious adverse event; SAE, serious adverse event.